<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="pmc-domain-id">692</journal-id><journal-id journal-id-type="pmc-domain">copd</journal-id><journal-id journal-id-type="publisher-id">copd</journal-id><journal-title-group><journal-title>International Journal of Chronic Obstructive Pulmonary Disease</journal-title></journal-title-group><issn pub-type="ppub">1176-9106</issn><issn pub-type="epub">1178-2005</issn><publisher><publisher-name>Dove Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12169042</article-id><article-id pub-id-type="pmcid-ver">PMC12169042.1</article-id><article-id pub-id-type="pmcaid">12169042</article-id><article-id pub-id-type="pmcaiid">12169042</article-id><article-id pub-id-type="pmid">40524720</article-id><article-id pub-id-type="doi">10.2147/COPD.S513573</article-id><article-id pub-id-type="publisher-id">513573</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Characteristics and Outcomes of People With COPD Who Experience Exacerbations While on Inhaled Triple Therapy: Results of the SIRIUS I Cohort Study in the US (2015&#8211;2019)</article-title><alt-title alt-title-type="running-authors">Nordon et al</alt-title><alt-title alt-title-type="running-title">Nordon et al</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Nordon</surname><given-names initials="C">Clementine</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carstens</surname><given-names initials="D">Donna</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fager&#229;s</surname><given-names initials="M">Malin</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0949-0101</contrib-id><name name-style="western"><surname>M&#252;llerov&#225;</surname><given-names initials="H">Hana</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Veeranki</surname><given-names initials="PS">Phani S</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alves</surname><given-names initials="JA">Jo&#227;o Andr&#233;</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Germack</surname><given-names initials="HD">Hayley D</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1428-4609</contrib-id><name name-style="western"><surname>Barnes</surname><given-names initials="TL">Timothy L</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1702-3201</contrib-id><name name-style="western"><surname>McCormack</surname><given-names initials="MC">Meredith C</given-names></name><xref rid="aff0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><aff id="aff0001"><label>1</label><institution>Respiratory Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca</institution>, <addr-line>Cambridge</addr-line>, <country>UK</country></aff><aff id="aff0002"><label>2</label><institution>US Medical Evidence, Biopharmaceuticals, AstraZeneca</institution>, <addr-line>Wilmington</addr-line>, <addr-line>DE</addr-line>, <country>USA</country></aff><aff id="aff0003"><label>3</label><institution>Global Medical, BioPharmaceuticals Medical, AstraZeneca</institution>, <addr-line>Gothenburg</addr-line>, <country>Sweden</country></aff><aff id="aff0004"><label>4</label><institution>Value &amp; Evidence Solutions, Optum Life Sciences</institution>, <addr-line>Eden Prairie</addr-line>, <addr-line>MN</addr-line>, <country>USA</country></aff><aff id="aff0005"><label>5</label><institution>School of Medicine, Johns Hopkins Medicine</institution>, <addr-line>Baltimore</addr-line>, <addr-line>MA</addr-line>, <country>USA</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Hana M&#252;llerov&#225;, <institution>AstraZeneca UK, Academy House</institution>, <addr-line>136&#160;Hills Road</addr-line>, <addr-line>Cambridge</addr-line>, <addr-line>CB2 8PA</addr-line>, <country>UK</country>, Email hana.muellerova@astrazeneca.com</corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>6</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue-id pub-id-type="pmc-issue-id">478627</issue-id><fpage>1851</fpage><lpage>1864</lpage><history><date date-type="received"><day>10</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>16</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-19 03:25:42.637"><day>19</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Nordon et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Nordon et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#8211; Non Commercial (unported, v4.0) License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="copd-20-1851.pdf"/><abstract><sec><title>Purpose</title><p>Many people with chronic obstructive pulmonary disease (COPD) continue to experience frequent moderate/severe exacerbations despite treatment with inhaled triple therapy (TT). We evaluated the baseline characteristics and outcomes (exacerbation rate, mortality, and healthcare resource utilization [HCRU]) of this COPD population, overall and by smoking status.</p></sec><sec><title>Patients and methods</title><p>A retrospective real-world cohort study of US patients was conducted using Optum&#8217;s deidentified Market Clarity Data, an integrated claims and electronic health record database (study period: 2015&#8211;2019). Patients eligible for inclusion were aged &#8805;40 years, with a COPD diagnosis, continuous 12-month (baseline) period of treatment with TT, and record of &#8805;2 moderate or &#8805;1 severe exacerbation during baseline. Follow-up was either variable (from end of baseline to death, loss to follow-up, or end of 2019) or fixed (12 months). Baseline characteristics and treatment patterns, crude incidence rates (IRs) for exacerbations and mortality (per 100 person-years [PYs]; variable follow-up), and HCRU and costs (12-month follow-up) were summarized descriptively.</p></sec><sec><title>Results</title><p>Of 4,920 patients in the TT cohort, mean (SD) age was 62.3 (9.7) years, 60.9% were female, and 68.0% were white; 46.5% of TT cohort patients with a history of smoking were current smokers. Hypertension (92.7%), ischemic heart disease (52.1%), and heart failure (40.1%) were the most prevalent cardiovascular comorbidities. Most patients received oral corticosteroids (89.6%) or antibiotics (92.8%) for exacerbation management during baseline. Add-on therapies included phosphodiesterase-4 inhibitors (10.4%) and leukotriene receptor antagonists (26.4%). During follow-up, IRs (95% CI) were 108.2 (104.7&#8211;111.8) per 100 PY for any moderate/severe exacerbation and 8.0 (7.4&#8211;8.6) per 100 PY for mortality. Exacerbation risk was similar by smoking status. During the 12-month follow-up, mean (SD) all-cause and COPD costs were $63,178 ($77,061) and $26,153 ($47,085), respectively.</p></sec><sec><title>Conclusion</title><p>There is high mortality and considerable HCRU and healthcare costs incurred by people with COPD experiencing frequent moderate/severe exacerbations while on TT. Optimization of COPD management and new therapies are needed to reduce disease burden in this population.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>COPD</kwd><kwd>burden of illness</kwd><kwd>exacerbation</kwd><kwd>inhaled triple therapy</kwd><kwd>mortality</kwd><kwd>healthcare resource utilization</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>AstraZeneca</institution><institution-id institution-id-type="open-funder-registry">10.13039/100004325</institution-id></institution-wrap></funding-source></award-group><funding-statement>This study was funded by AstraZeneca.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="3"/><ref-count count="41"/><page-count count="14"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality and morbidity globally, with a substantial and increasing economic and societal burden.<xref rid="cit0001" ref-type="bibr">1&#8211;5</xref> According to 2019 global estimates, there were 212 million people living with COPD, with 3.3 million COPD-related deaths.<xref rid="cit0004" ref-type="bibr">4</xref> In the US, COPD affects an estimated 14.2 million adults, and it is the sixth leading cause of death with 144,752 COPD-related fatalities reported for 2019.<xref rid="cit0006" ref-type="bibr">6</xref>,<xref rid="cit0007" ref-type="bibr">7</xref> COPD-related healthcare expenses are expected to increase globally over the next few years and are projected to cost $60.5 billion in the US in 2029.<xref rid="cit0008" ref-type="bibr">8</xref>,<xref rid="cit0009" ref-type="bibr">9</xref> Exacerbations are a key feature of COPD and present a clinical and healthcare challenge worldwide; most people with COPD experience exacerbations of varying severity and frequency, with worsening symptoms and declining lung function over their lifetime.<xref rid="cit0010" ref-type="bibr">10</xref>,<xref rid="cit0011" ref-type="bibr">11</xref> Exacerbations also vary in severity and can be categorized as mild (requiring treatment with short-acting bronchodilators only), moderate (requiring add-on medication), and severe (requiring hospitalization or an emergency room [ER] visit).<xref rid="cit0002" ref-type="bibr">2</xref> Frequent exacerbators are defined as those that experience &#8805;2 exacerbation events within a year or &#8805;1 exacerbation requiring hospitalization, while super exacerbators are defined as those with &#8805;3 exacerbations in a year.<xref rid="cit0002" ref-type="bibr">2</xref>,<xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0013" ref-type="bibr">13</xref></p><p>The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report recommends management of COPD with single or multiple maintenance inhaled therapies, depending on exacerbation patterns and dyspnea intensity.<xref rid="cit0002" ref-type="bibr">2</xref> In people with &#8805;2 moderate and/or &#8805;1 severe exacerbation within a year, initial treatment with inhaled dual therapy (long-acting muscarinic antagonist [LAMA] and long-acting &#946;<sub>2</sub>-agonist [LABA]) is recommended; inhaled triple therapy (LAMA+LABA with inhaled corticosteroids [ICS]) is also recommended as the initial treatment option for patients with high eosinophil count (&#8805;300 cells/&#956;L) or as step-up therapy for those with an eosinophil count of &#8805;100 cells/&#956;L who continue to experience exacerbations.<xref rid="cit0002" ref-type="bibr">2</xref> Beyond inhaled medications, add-on therapies (eg, long-term macrolides, N-acetylcysteine, long-term oral glucocorticoids, phosphodiesterase 3 and 4 inhibitors, or mucolytics) are also considered; however, these have limited risk/benefit profiles.<xref rid="cit0002" ref-type="bibr">2</xref>,<xref rid="cit0014" ref-type="bibr">14</xref>,<xref rid="cit0015" ref-type="bibr">15</xref> In addition to pharmacological therapy, smoking cessation is a priority in COPD management, and, yet, observational studies suggest that up to 30% to 40% of people with COPD remain current smokers.<xref rid="cit0002" ref-type="bibr">2</xref>,<xref rid="cit0016" ref-type="bibr">16</xref>,<xref rid="cit0017" ref-type="bibr">17</xref> Despite these available therapeutic options, and challenges association with smoking cessation, it is estimated that 30% to 60% of patients continue to experience moderate to severe exacerbations while receiving dual or triple inhaled therapy, highlighting an unmet medical need for more effective treatment options for the management of COPD exacerbations.<xref rid="cit0018" ref-type="bibr">18&#8211;23</xref></p><p>Several monoclonal antibodies targeting different inflammatory pathways are currently under development, and one has been recently approved, aimed at decreasing exacerbation risk and improving symptoms in people with COPD who continue to experience exacerbations while on inhaled dual or triple therapy.<xref rid="cit0024" ref-type="bibr">24&#8211;27</xref> However, the patients enrolled in clinical trials may differ from the heterogenous real-world population<xref rid="cit0028" ref-type="bibr">28</xref> and little is known about the characteristics and clinical outcomes of this COPD population in routine clinical practice. The primary aim of this study was to describe clinical characteristics, healthcare resource utilization (HCRU) and costs, and exacerbation and mortality rates in people with COPD who experienced moderate or severe exacerbations despite being on maintenance maximal inhaled triple therapy, overall and stratified by smoking status.</p></sec><sec id="s0002"><title>Methods</title><sec id="s0002-s2001"><title>Study Design and Data Source</title><p>The SIRIUS I study was a retrospective real-world cohort study using Optum&#8217;s deidentified Market Clarity Data (Market Clarity) in the US (2015&#8211;2019). Market Clarity deterministically links medical and pharmacy claims with electronic health record data from providers across the continuum of care.<xref rid="cit0029" ref-type="bibr">29</xref> The base study population was people with COPD who experienced &#8805;2 moderate or &#8805;1 severe COPD exacerbation while on maintenance inhaled dual or triple therapy (<xref rid="f0001" ref-type="fig">Figure 1</xref>). People with COPD were defined as those with &#8805;1 inpatient or outpatient visit claim with a COPD diagnosis code (using <italic toggle="yes">International Classification of Diseases, 9th</italic> or <italic toggle="yes">10th Revision</italic> [<italic toggle="yes">ICD-9/10</italic>]; <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">Table S1</ext-link></underline>) between January 1, 2015, and December 31, 2018, and aged &#8805;40 years at the first COPD diagnosis. Use of maintenance inhaled dual or triple therapy was defined as (1) &#8805;2 prescriptions for single or multiple inhaled dual or triple therapy (LAMA/ICS; LABA/ICS; LAMA/LABA; LAMA/LABA/ICS) within a 90-day period, with the first prescription (start of the 12-month baseline period) occurring after COPD diagnosis and (2) another dispensation of inhaled dual/triple therapy in the 30 days before the end of the 12-month baseline period. For multiple inhaler therapy, an overlap of &#8805;30 days between 2 different inhalers was required. Exacerbation history during the baseline period was characterized by either &#8805;2 moderate exacerbations (defined as an ER visit with a primary diagnosis code for COPD or an outpatient visit with a primary diagnosis code for COPD and dispensation of systemic corticosteroids and/or GOLD-recommended antibiotics within 7 days of the visit) or &#8805;1 severe exacerbation (defined as a hospitalization with &#8805;1 overnight stay with a primary diagnosis code for COPD).<xref rid="cit0002" ref-type="bibr">2</xref> Patients were excluded if they had incomplete data availability during baseline; had a diagnosis of cystic fibrosis, interstitial lung disease, or alpha-1 antitrypsin deficiency; or were participating in a clinical trial (<xref rid="f0002" ref-type="fig">Figure 2</xref>).
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>Study Design and Observation Period.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="COPD-20-1851-g0001.jpg"/><attrib><bold>Abbreviations</bold>: COPD, chronic obstructive pulmonary disease; HCRU, healthcare resource utilization.</attrib></fig>
<fig position="float" id="f0002" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><p>Study Population.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="COPD-20-1851-g0002.jpg"/><attrib><bold>Abbreviations</bold>: COPD, chronic obstructive pulmonary disease; DT, dual therapy; TT, triple therapy.</attrib></fig></p><p>The primary population of interest was patients on maintenance inhaled triple therapy during baseline (&#8220;triple therapy cohort&#8221;), defined as &#8805;1 dispensation of inhaled triple therapy during baseline. Patients in the triple therapy cohort with information on smoking history were further stratified according to smoking status (current or former smokers). The secondary population of interest was patients who received either inhaled dual or triple therapy (&#8220;dual/triple therapy cohort&#8221;).</p><p>Day 1 following the end of the baseline period constituted the start of the follow-up period, which ended at the earliest of death, disenrollment, or December 31, 2019. For HCRU and direct healthcare cost measures, a 12-month follow-up was required.</p></sec><sec id="s0002-s2002"><title>Study Variables</title><p>Baseline characteristics included age, sex, payer type (commercial, managed Medicare, Medicaid, multiple, unknown), smoking status (current/former/never smoked), body mass index, and number and severity of exacerbations (moderate or severe). Comorbidity burden was assessed through Charlson Comorbidity Index (CCI) scores<xref rid="cit0030" ref-type="bibr">30</xref> and prevalence of prespecified comorbidities of interest (ischemic heart disease, heart failure, arrhythmia, type 2 diabetes, chronic kidney disease [CKD], and asthma).</p><p>Medical specialties of the initial inhaled treatment prescriber (within the baseline period) and patterns of COPD and other medication use (long-acting and short-acting inhalers, oral corticosteroids [OCS], GOLD-recommended antibiotics, methylxanthines, phosphodiesterase 4 [PDE4] inhibitors, and leukotriene receptor antagonists [LTRAs]) were also described.</p><p>COPD exacerbation (any severity) and all-cause mortality were recorded during follow-up. HCRU and healthcare costs, including all-cause and COPD-related outpatient visits, ER visits, and hospitalizations, were identified using Current Procedural Terminology/Healthcare Common Procedure Coding System codes and reported for baseline and the first 12 months of follow-up. Costs per patient-year (PPY) were reported and adjusted to 2021 US dollars using the annual medical care component of the Consumer Price Index.<xref rid="cit0031" ref-type="bibr">31</xref></p></sec><sec id="s0002-s2003"><title>Statistical Analysis</title><p>Baseline characteristics and outcomes were described for the triple therapy cohort (overall and stratified by smoking status [current or former smokers]). Baseline characteristics, HCRU, and costs were summarized using descriptive statistics. Crude incidence rates (IRs) of a first exacerbation (any severity, moderate, severe) and mortality rates were calculated as the ratio between the number of first events during follow-up and the number of 100 person-years (PY) of follow-up; 95% CIs were estimated using the exact Poisson method. IRs were also stratified by sex and age. IRs of all-cause mortality were calculated without considering the competing risk of an exacerbation. Missing codes for a given comorbidity or healthcare event were not measurable or imputed. Results were also summarized for the dual/triple therapy cohort.</p></sec></sec><sec id="s0003"><title>Results</title><p>A total of 16,968 patients comprised the dual/triple therapy cohort, including 4,920 (29.0%) in the triple therapy cohort (<xref rid="f0002" ref-type="fig">Figure 2</xref>). Of the triple therapy cohort, 144 (2.9%) received fixed (ie, single inhaler) triple therapy.</p><sec id="s0003-s2001"><title>Characteristics of the Triple Therapy Cohort</title><p>Among the patients in the triple therapy cohort, 1,623 (33.0%) had a recorded history of smoking; of these, 755 (46.5%) were current smokers and 868 (53.5%) were former smokers (<xref rid="t0001" ref-type="table">Table 1</xref>). Sociodemographic characteristics of patients in the triple therapy cohort and current and former smoker subsets were broadly comparable. Most of the triple therapy cohort were female (60.9%); this proportion was slightly higher among current smokers (62.8%) (<xref rid="t0001" ref-type="table">Table 1</xref>). Mean (SD) age was 62.3 (9.7) years for the triple therapy cohort and younger in current smokers (59.4 [8.7] years).</p><p>With respect to comorbidities, 52.1% of patients had ischemic heart disease, 49.7% had asthma, 40.1% had heart failure, 38.8% had type 2 diabetes, and 13.0% had CKD (<xref rid="t0001" ref-type="table">Table 1</xref>). The prevalence of cardiovascular disease was greater in former vs current smokers, in particular, arrhythmia (50.1% vs 44.7%, respectively) and heart failure (44.7% vs 35.8%, respectively). During the 12-month baseline period, 55.6% of patients had &#8805;2 moderate exacerbations (and no severe) and 44.4% had &#8805;1 severe exacerbation; the proportion who had &#8805;1 severe exacerbation was 44.5% in current smokers and 49.1% in former smokers. Baseline characteristics of the dual/triple therapy cohort are described in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">Table S2</ext-link></underline>.
<table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1</label><caption><p>Baseline Sociodemographics and Comorbidities of Patients in the Triple Therapy Cohort and Stratified by Smoking Status<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Triple Therapy (N=4,920)</th><th rowspan="1" colspan="1">Current Smokers (n=755)</th><th rowspan="1" colspan="1">Former Smokers (n=868)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>Female sex</bold></td><td rowspan="1" colspan="1">2,998 (60.9)</td><td rowspan="1" colspan="1">474 (62.8)</td><td rowspan="1" colspan="1">493 (56.8)</td></tr><tr><td rowspan="1" colspan="1"><bold>Age, mean (SD), years</bold></td><td rowspan="1" colspan="1">62.3 (9.7)</td><td rowspan="1" colspan="1">59.4 (8.7)</td><td rowspan="1" colspan="1">64.9 (10.0)</td></tr><tr><td colspan="4" rowspan="1"><bold>Age category, n (%)</bold></td></tr><tr><td rowspan="1" colspan="1">40&#8211;49 years</td><td rowspan="1" colspan="1">395 (8.0)</td><td rowspan="1" colspan="1">81 (10.7)</td><td rowspan="1" colspan="1">45 (5.2)</td></tr><tr><td rowspan="1" colspan="1">50&#8211;64 years</td><td rowspan="1" colspan="1">2,690 (54.7)</td><td rowspan="1" colspan="1">492 (65.2)</td><td rowspan="1" colspan="1">408 (47.0)</td></tr><tr><td rowspan="1" colspan="1">65&#8211;74 years</td><td rowspan="1" colspan="1">1,205 (24.5)</td><td rowspan="1" colspan="1">136 (18.0)</td><td rowspan="1" colspan="1">241 (27.8)</td></tr><tr><td rowspan="1" colspan="1">&#8805;75 years</td><td rowspan="1" colspan="1">630 (12.8)</td><td rowspan="1" colspan="1">46 (6.1)</td><td rowspan="1" colspan="1">174 (20.1)</td></tr><tr><td colspan="4" rowspan="1"><bold>Race, n (%)</bold></td></tr><tr><td rowspan="1" colspan="1">White</td><td rowspan="1" colspan="1">3,347 (68.0)</td><td rowspan="1" colspan="1">585 (77.5)</td><td rowspan="1" colspan="1">717 (82.6)</td></tr><tr><td rowspan="1" colspan="1">African American</td><td rowspan="1" colspan="1">589 (12.0)</td><td rowspan="1" colspan="1">131 (17.4)</td><td rowspan="1" colspan="1">106 (12.2)</td></tr><tr><td rowspan="1" colspan="1">Asian/other/unknown</td><td rowspan="1" colspan="1">984 (20.0)</td><td rowspan="1" colspan="1">39 (5.2)</td><td rowspan="1" colspan="1">45 (5.2)</td></tr><tr><td colspan="4" rowspan="1"><bold>Region in the US, n (%)</bold></td></tr><tr><td rowspan="1" colspan="1">Northeast</td><td rowspan="1" colspan="1">1,014 (20.6)</td><td rowspan="1" colspan="1">107 (14.2)</td><td rowspan="1" colspan="1">157 (18.1)</td></tr><tr><td rowspan="1" colspan="1">Midwest</td><td rowspan="1" colspan="1">2,063 (41.9)</td><td rowspan="1" colspan="1">403 (53.4)</td><td rowspan="1" colspan="1">432 (49.8)</td></tr><tr><td rowspan="1" colspan="1">South</td><td rowspan="1" colspan="1">1,242 (25.2)</td><td rowspan="1" colspan="1">174 (23.1)</td><td rowspan="1" colspan="1">161 (18.6)</td></tr><tr><td rowspan="1" colspan="1">West</td><td rowspan="1" colspan="1">376 (7.6)</td><td rowspan="1" colspan="1">50 (6.6)</td><td rowspan="1" colspan="1">87 (10.0)</td></tr><tr><td rowspan="1" colspan="1">Other/unknown</td><td rowspan="1" colspan="1">225 (4.6)</td><td rowspan="1" colspan="1">21 (2.8)</td><td rowspan="1" colspan="1">31 (3.6)</td></tr><tr><td colspan="4" rowspan="1"><bold>Payer, n (%)</bold></td></tr><tr><td rowspan="1" colspan="1">Commercial only</td><td rowspan="1" colspan="1">1,058 (21.5)</td><td rowspan="1" colspan="1">157 (20.8)</td><td rowspan="1" colspan="1">188 (21.7)</td></tr><tr><td rowspan="1" colspan="1">Medicare Advantage only</td><td rowspan="1" colspan="1">2,150 (43.7)</td><td rowspan="1" colspan="1">273 (36.2)</td><td rowspan="1" colspan="1">460 (53.0)</td></tr><tr><td rowspan="1" colspan="1">Medicaid only</td><td rowspan="1" colspan="1">1,210 (24.6)</td><td rowspan="1" colspan="1">246 (32.6)</td><td rowspan="1" colspan="1">127 (14.6)</td></tr><tr><td rowspan="1" colspan="1">Multiple known</td><td rowspan="1" colspan="1">206 (4.2)</td><td rowspan="1" colspan="1">24 (3.2)</td><td rowspan="1" colspan="1">32 (3.7)</td></tr><tr><td rowspan="1" colspan="1">None/unknown</td><td rowspan="1" colspan="1">296 (6.0)</td><td rowspan="1" colspan="1">55 (7.3)</td><td rowspan="1" colspan="1">61 (7.0)</td></tr><tr><td colspan="4" rowspan="1"><bold>Smoking status, n (%)</bold></td></tr><tr><td rowspan="1" colspan="1">Current smoker</td><td rowspan="1" colspan="1">755 (15.4)</td><td rowspan="1" colspan="1">755 (100.0)</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="1" colspan="1">Former smoker</td><td rowspan="1" colspan="1">868 (17.6)</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">868 (100.0)</td></tr><tr><td rowspan="1" colspan="1">Never smoked</td><td rowspan="1" colspan="1">75 (1.5)</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">47 (1.0)</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="1" colspan="1">Missing</td><td rowspan="1" colspan="1">3,175 (64.5)</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td colspan="4" rowspan="1"><bold>Charlson Comorbidity Index score, n (%)</bold></td></tr><tr><td rowspan="1" colspan="1">&#8804;2</td><td rowspan="1" colspan="1">2,392 (48.6)</td><td rowspan="1" colspan="1">386 (51.1)</td><td rowspan="1" colspan="1">383 (44.1)</td></tr><tr><td rowspan="1" colspan="1">3&#8211;4</td><td rowspan="1" colspan="1">1,593 (32.4)</td><td rowspan="1" colspan="1">239 (31.7)</td><td rowspan="1" colspan="1">285 (32.8)</td></tr><tr><td rowspan="1" colspan="1">&#8805;5</td><td rowspan="1" colspan="1">935 (19.0)</td><td rowspan="1" colspan="1">130 (17.2)</td><td rowspan="1" colspan="1">200 (23.0)</td></tr><tr><td rowspan="1" colspan="1"><bold>Charlson Comorbidity Index score, mean (SD)</bold></td><td rowspan="1" colspan="1">2.82 (2.10)</td><td rowspan="1" colspan="1">2.72 (2.11)</td><td rowspan="1" colspan="1">3.03 (2.20)</td></tr><tr><td rowspan="1" colspan="1"><bold>Cardiovascular conditions, n (%)<sup>b</sup></bold></td><td rowspan="1" colspan="1"><bold>n=4,415</bold></td><td rowspan="1" colspan="1"><bold>n=684</bold></td><td rowspan="1" colspan="1"><bold>n=795</bold></td></tr><tr><td rowspan="1" colspan="1">Hypertensive disease</td><td rowspan="1" colspan="1">4,093 (92.7)</td><td rowspan="1" colspan="1">633 (92.5)</td><td rowspan="1" colspan="1">727 (91.5)</td></tr><tr><td rowspan="1" colspan="1">Ischemic heart disease<sup>c</sup></td><td rowspan="1" colspan="1">2,299 (52.1)</td><td rowspan="1" colspan="1">352 (51.5)</td><td rowspan="1" colspan="1">429 (54.0)</td></tr><tr><td rowspan="1" colspan="1">Arrhythmias</td><td rowspan="1" colspan="1">2,014 (45.6)</td><td rowspan="1" colspan="1">306 (44.7)</td><td rowspan="1" colspan="1">398 (50.1)</td></tr><tr><td rowspan="1" colspan="1">Heart failure</td><td rowspan="1" colspan="1">1,771 (40.1)</td><td rowspan="1" colspan="1">245 (35.8)</td><td rowspan="1" colspan="1">355 (44.7)</td></tr><tr><td rowspan="1" colspan="1">Cardiomyopathy</td><td rowspan="1" colspan="1">1,229 (27.8)</td><td rowspan="1" colspan="1">186 (27.2)</td><td rowspan="1" colspan="1">237 (29.8)</td></tr><tr><td rowspan="1" colspan="1">Pulmonary embolism</td><td rowspan="1" colspan="1">293 (6.6)</td><td rowspan="1" colspan="1">56 (8.2)</td><td rowspan="1" colspan="1">64 (8.1)</td></tr><tr><td colspan="4" rowspan="1"><bold>Other conditions, n (%)</bold></td></tr><tr><td rowspan="1" colspan="1">Hyperlipidemia</td><td rowspan="1" colspan="1">3,452 (70.2)</td><td rowspan="1" colspan="1">523 (69.3)</td><td rowspan="1" colspan="1">604 (69.6)</td></tr><tr><td rowspan="1" colspan="1">Asthma</td><td rowspan="1" colspan="1">2,446 (49.7)</td><td rowspan="1" colspan="1">385 (51.0)</td><td rowspan="1" colspan="1">411 (47.4)</td></tr><tr><td rowspan="1" colspan="1">Type 2 diabetes</td><td rowspan="1" colspan="1">1,908 (38.8)</td><td rowspan="1" colspan="1">292 (38.7)</td><td rowspan="1" colspan="1">322 (37.1)</td></tr><tr><td rowspan="1" colspan="1">Obesity (BMI &#8805;30 kg/m<sup>2</sup>)<sup>d</sup></td><td rowspan="1" colspan="1">1,775 (36.1)</td><td rowspan="1" colspan="1">317 (42.0)</td><td rowspan="1" colspan="1">386 (44.5)</td></tr><tr><td rowspan="1" colspan="1">Chronic kidney disease</td><td rowspan="1" colspan="1">641 (13.0)</td><td rowspan="1" colspan="1">90 (11.9)</td><td rowspan="1" colspan="1">143 (16.5)</td></tr><tr><td rowspan="1" colspan="1">Lung cancer</td><td rowspan="1" colspan="1">308 (6.3)</td><td rowspan="1" colspan="1">43 (5.7)</td><td rowspan="1" colspan="1">66 (7.6)</td></tr><tr><td colspan="4" rowspan="1"><bold>Exacerbation pattern, n (%)</bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;2 moderate exacerbations</td><td rowspan="1" colspan="1">2,737 (55.6)</td><td rowspan="1" colspan="1">419 (55.5)</td><td rowspan="1" colspan="1">442 (50.9)</td></tr><tr><td rowspan="1" colspan="1">&#8805;1 severe exacerbation</td><td rowspan="1" colspan="1">2,183 (44.4)</td><td rowspan="1" colspan="1">336 (44.5)</td><td rowspan="1" colspan="1">426 (49.1)</td></tr><tr><td rowspan="1" colspan="1"><bold>Follow-up time, mean (SD), months</bold></td><td rowspan="1" colspan="1">21.2 (12.4)</td><td rowspan="1" colspan="1">20.2 (12.6)</td><td rowspan="1" colspan="1">20.2 (12.4)</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><bold>Notes</bold>: <sup>a</sup>A total of 1,623 patients in the triple therapy cohort had a recorded history of smoking; the stratified analyses were conducted in this subset of the triple therapy cohort. <sup>b</sup>The n values for the &#8220;Cardiovascular conditions&#8221; category represent the number of patients with available data in each analysis group. <sup>c</sup>Ischemic heart disease includes coronary artery diseases, acute myocardial infarction, and unstable angina. <sup>d</sup>Obesity was defined as BMI &#8805;30 kg/m<sup>2</sup> or using diagnosis code.</p></fn><fn id="tfn0002"><p><bold>Abbreviations</bold>: BMI, body mass index; N/A, not applicable.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s0003-s2002"><title>Prescriber and Treatment Patterns in the Triple Therapy Cohort</title><p>Prescribers and treatment patterns at baseline are described for the triple therapy cohort in <xref rid="t0002" ref-type="table">Table 2</xref>. In addition to inhaled triple therapy, the mean (SD) cumulative durations of exposure to other COPD-related medications (in patients receiving these medications), were 222.6 (139.4) days for PDE4 inhibitors and 265.7 (130.5) days for LTRAs. Most patients received antibiotics (92.8%) and OCS (89.6%), which were prescribed for mean (SD) cumulative durations of 44.8 (71.0) days and 72.5 (102.0) days, respectively. Mean (SD) duration of exposure was higher among the former vs current smokers for PDE4 inhibitors (223.0 [150.7] days vs 207.0 [134.0] days), LTRAs (265.0 [126.8] days vs 252.4 [128.2] days), and exacerbation-management medication (OCS, 79.4 [109.9] days vs 63.1 [90.6] days; antibiotics, 49.4 [78.8] days vs 41.2 [63.0] days) (<xref rid="t0002" ref-type="table">Table 2</xref>). Prescriber and treatment patterns for the dual/triple therapy cohort are described in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">Table S3</ext-link></underline>.
<table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2</label><caption><p>Prescriber and Treatment Patterns During Baseline for Patients in the Triple Therapy Cohort and Stratified by Smoking Status<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Triple Therapy (N=4,920)</th><th rowspan="1" colspan="1">Current Smokers (n=755)</th><th rowspan="1" colspan="1">Former Smokers (n=868)</th></tr></thead><tbody><tr><td colspan="4" rowspan="1"><bold>Initial treatment prescriber specialty, n (%)</bold></td></tr><tr><td rowspan="1" colspan="1">Primary care physician</td><td rowspan="1" colspan="1">2,352 (47.8)</td><td rowspan="1" colspan="1">359 (47.6)</td><td rowspan="1" colspan="1">456 (52.5)</td></tr><tr><td rowspan="1" colspan="1">Pulmonology</td><td rowspan="1" colspan="1">1,196 (24.3)</td><td rowspan="1" colspan="1">147 (19.5)</td><td rowspan="1" colspan="1">240 (27.7)</td></tr><tr><td rowspan="1" colspan="1">Other<sup>b</sup></td><td rowspan="1" colspan="1">60 (1.2)</td><td rowspan="1" colspan="1">12 (1.6)</td><td rowspan="1" colspan="1">9 (1.0)</td></tr><tr><td rowspan="1" colspan="1">Missing/unknown</td><td rowspan="1" colspan="1">1,312 (26.7)</td><td rowspan="1" colspan="1">237 (31.4)</td><td rowspan="1" colspan="1">163 (18.8)</td></tr><tr><td colspan="4" rowspan="1"><bold>Inhaled maintenance therapy medications</bold></td></tr><tr><td colspan="4" rowspan="1"><bold><italic toggle="yes">Any LAMA (free dose or combination)</italic></bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;1 Dispensation, n (%)</td><td rowspan="1" colspan="1">4,854 (98.7)</td><td rowspan="1" colspan="1">742 (98.3)</td><td rowspan="1" colspan="1">860 (99.1)</td></tr><tr><td rowspan="1" colspan="1">Cumulative number of days, mean (SD)<sup>c</sup></td><td rowspan="1" colspan="1">296.2 (112.8)</td><td rowspan="1" colspan="1">287.4 (111.5)</td><td rowspan="1" colspan="1">299.0 (113.1)</td></tr><tr><td colspan="4" rowspan="1"><bold><italic toggle="yes">LAMA (free dose)</italic></bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;1 Dispensation, n (%)</td><td rowspan="1" colspan="1">4,533 (92.1)</td><td rowspan="1" colspan="1">691 (91.5)</td><td rowspan="1" colspan="1">794 (91.5)</td></tr><tr><td rowspan="1" colspan="1">Cumulative number of days, mean (SD)<sup>c</sup></td><td rowspan="1" colspan="1">289.5 (113.8)</td><td rowspan="1" colspan="1">282.2 (112.2)</td><td rowspan="1" colspan="1">290.8 (115.9)</td></tr><tr><td colspan="4" rowspan="1"><bold><italic toggle="yes">LAMA/LABA (single inhaler combination)</italic></bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;1 Dispensation, n (%)</td><td rowspan="1" colspan="1">533 (10.8)</td><td rowspan="1" colspan="1">71 (9.4)</td><td rowspan="1" colspan="1">109 (12.6)</td></tr><tr><td rowspan="1" colspan="1">Cumulative number of days, mean (SD)<sup>c</sup></td><td rowspan="1" colspan="1">178.8 (127.9)</td><td rowspan="1" colspan="1">182.9 (126.1)</td><td rowspan="1" colspan="1">189.6 (138.7)</td></tr><tr><td colspan="4" rowspan="1"><bold><italic toggle="yes">Triple therapy (fixed dose)</italic></bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;1 Dispensation, n (%)</td><td rowspan="1" colspan="1">144 (2.9)</td><td rowspan="1" colspan="1">21 (2.8)</td><td rowspan="1" colspan="1">29 (3.3)</td></tr><tr><td rowspan="1" colspan="1">Cumulative number of days, mean (SD)<sup>c</sup></td><td rowspan="1" colspan="1">214.6 (140.0)</td><td rowspan="1" colspan="1">260.5 (128.5)</td><td rowspan="1" colspan="1">195.9 (141.1)</td></tr><tr><td colspan="4" rowspan="1"><bold><italic toggle="yes">Any LABA (free dose or combination)</italic></bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;1 Dispensation, n (%)</td><td rowspan="1" colspan="1">4,920 (100.0)</td><td rowspan="1" colspan="1">755 (100.00)</td><td rowspan="1" colspan="1">868 (100.00)</td></tr><tr><td rowspan="1" colspan="1">Cumulative number of days, mean (SD)<sup>c</sup></td><td rowspan="1" colspan="1">337.7 (100.8)</td><td rowspan="1" colspan="1">332.3 (96.1)</td><td rowspan="1" colspan="1">334.9 (92.6)</td></tr><tr><td colspan="4" rowspan="1"><bold><italic toggle="yes">LABA (free dose)</italic></bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;1 Dispensation, n (%)</td><td rowspan="1" colspan="1">124 (2.5)</td><td rowspan="1" colspan="1">15 (2.0)</td><td rowspan="1" colspan="1">28 (3.2)</td></tr><tr><td rowspan="1" colspan="1">Cumulative number of days, mean (SD)<sup>c</sup></td><td rowspan="1" colspan="1">127.0 (119.0)</td><td rowspan="1" colspan="1">170.0 (161.4)</td><td rowspan="1" colspan="1">127.0 (128.8)</td></tr><tr><td colspan="4" rowspan="1"><bold><italic toggle="yes">ICS/LABA (single inhaler combination)</italic></bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;1 Dispensation, n (%)</td><td rowspan="1" colspan="1">4,742 (96.4)</td><td rowspan="1" colspan="1">726 (96.2)</td><td rowspan="1" colspan="1">825 (95.1)</td></tr><tr><td rowspan="1" colspan="1">Cumulative number of days, mean (SD)<sup>c</sup></td><td rowspan="1" colspan="1">321.9 (104.4)</td><td rowspan="1" colspan="1">318.2 (100.5)</td><td rowspan="1" colspan="1">317.2 (100.3)</td></tr><tr><td colspan="4" rowspan="1"><bold><italic toggle="yes">Any ICS (free dose or combination)</italic></bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;1 Dispensation, n (%)</td><td rowspan="1" colspan="1">4,907 (99.7)</td><td rowspan="1" colspan="1">754 (99.9)</td><td rowspan="1" colspan="1">863 (99.4)</td></tr><tr><td rowspan="1" colspan="1">Cumulative number of days, mean (SD)<sup>c</sup></td><td rowspan="1" colspan="1">330.6 (106.2)</td><td rowspan="1" colspan="1">325.8 (101.0)</td><td rowspan="1" colspan="1">326.9 (101.5)</td></tr><tr><td colspan="4" rowspan="1"><bold><italic toggle="yes">ICS (free dose)</italic></bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;1 Dispensation, n (%)</td><td rowspan="1" colspan="1">498 (10.1)</td><td rowspan="1" colspan="1">68 (9.0)</td><td rowspan="1" colspan="1">94 (10.8)</td></tr><tr><td rowspan="1" colspan="1">Cumulative number of days, mean (SD)<sup>c</sup></td><td rowspan="1" colspan="1">147.2 (131.0)</td><td rowspan="1" colspan="1">155.9 (139.8)</td><td rowspan="1" colspan="1">167.3 (145.9)</td></tr><tr><td colspan="4" rowspan="1"><bold>Patterns of add-on COPD medications</bold></td></tr><tr><td colspan="4" rowspan="1"><bold><italic toggle="yes">GOLD-recommended antibiotics</italic></bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;1 Dispensation, n (%)</td><td rowspan="1" colspan="1">4,566 (92.8)</td><td rowspan="1" colspan="1">704 (93.3)</td><td rowspan="1" colspan="1">796 (91.7)</td></tr><tr><td rowspan="1" colspan="1">Cumulative number of days, mean (SD)<sup>c</sup></td><td rowspan="1" colspan="1">44.8 (71.0)</td><td rowspan="1" colspan="1">41.2 (63.0)</td><td rowspan="1" colspan="1">49.4 (78.8)</td></tr><tr><td colspan="4" rowspan="1"><bold><italic toggle="yes">Oral corticosteroids</italic></bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;1 Dispensation, n (%)</td><td rowspan="1" colspan="1">4,408 (89.6)</td><td rowspan="1" colspan="1">690 (91.4)</td><td rowspan="1" colspan="1">775 (89.3)</td></tr><tr><td rowspan="1" colspan="1">Cumulative number of days, mean (SD)<sup>c</sup></td><td rowspan="1" colspan="1">72.5 (102.0)</td><td rowspan="1" colspan="1">63.1 (90.6)</td><td rowspan="1" colspan="1">79.4 (109.9)</td></tr><tr><td colspan="4" rowspan="1"><bold><italic toggle="yes">Phosphodiesterase 4 inhibitors</italic></bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;1 Dispensation, n (%)</td><td rowspan="1" colspan="1">509 (10.4)</td><td rowspan="1" colspan="1">88 (11.7)</td><td rowspan="1" colspan="1">98 (11.3)</td></tr><tr><td rowspan="1" colspan="1">Cumulative number of days, mean (SD)<sup>c</sup></td><td rowspan="1" colspan="1">222.6 (139.4)</td><td rowspan="1" colspan="1">207.0 (134.1)</td><td rowspan="1" colspan="1">223.0 (150.7)</td></tr><tr><td colspan="4" rowspan="1"><bold><italic toggle="yes">Leukotriene receptor antagonists</italic></bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;1 Dispensation, n (%)</td><td rowspan="1" colspan="1">1,301 (26.4)</td><td rowspan="1" colspan="1">170 (22.5)</td><td rowspan="1" colspan="1">200 (23.0)</td></tr><tr><td rowspan="1" colspan="1">Cumulative number of days, mean (SD)<sup>c</sup></td><td rowspan="1" colspan="1">265.7 (130.5)</td><td rowspan="1" colspan="1">252.4 (128.2)</td><td rowspan="1" colspan="1">265.0 (126.8)</td></tr><tr><td colspan="4" rowspan="1"><bold>Methylxanthines<sup>d</sup></bold></td></tr><tr><td rowspan="1" colspan="1">&#8805;1 Dispensation, n (%)</td><td rowspan="1" colspan="1">269 (5.5)</td><td rowspan="1" colspan="1">36 (4.8)</td><td rowspan="1" colspan="1">53 (6.1)</td></tr><tr><td rowspan="1" colspan="1">Cumulative number of days, mean (SD)<sup>c</sup></td><td rowspan="1" colspan="1">246.3 (141.4)</td><td rowspan="1" colspan="1">241.4 (142.5)</td><td rowspan="1" colspan="1">256.9 (136.4)</td></tr><tr><td colspan="4" rowspan="1"><bold>Short-acting</bold> &#946;<bold>-agonists, &#8805;1 dispensation, n (%)</bold></td></tr><tr><td rowspan="1" colspan="1">Free dose or in combination</td><td rowspan="1" colspan="1">4,631 (94.1)</td><td rowspan="1" colspan="1">734 (97.2)</td><td rowspan="1" colspan="1">790 (91.0)</td></tr><tr><td rowspan="1" colspan="1">Alone</td><td rowspan="1" colspan="1">4,454 (90.5)</td><td rowspan="1" colspan="1">710 (94.0)</td><td rowspan="1" colspan="1">752 (86.6)</td></tr><tr><td rowspan="1" colspan="1">In combination with short-acting antimuscarinic agents</td><td rowspan="1" colspan="1">1,586 (32.2)</td><td rowspan="1" colspan="1">265 (35.1)</td><td rowspan="1" colspan="1">276 (31.8)</td></tr></tbody></table><table-wrap-foot><fn id="tfn0003"><p><bold>Notes</bold>: <sup>a</sup>A total of 1,623 patients in the triple therapy cohort had a recorded history of smoking; the stratified analyses were conducted in this subset of the triple therapy cohort. <sup>b&#8220;</sup>Other&#8221; category includes allergy/immunology, gastroenterology, and otolaryngology specialists. <sup>c</sup>In patients with &#8805;1 dispensation. <sup>d</sup>Formulation type (sustained release or fast acting) not specified.</p></fn><fn id="tfn0004"><p><bold>Abbreviations</bold>: COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting &#946;-agonist; LAMA, long-acting muscarinic antagonist.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s0003-s2003"><title>Outcomes of Exacerbations and Death</title><p>During a mean (SD) follow-up of 21.2 (12.4) months, 71.8% of patients in the triple therapy cohort had &#8805;1 exacerbation of any severity (IR: 108.2 [95% CI 104.7&#8211;111.8] per 100 PY), 64.2% had &#8805;1 moderate exacerbation (IR: 83.4 [95% CI 80.5&#8211;86.4] per 100 PY), and 32.3% had &#8805;1 severe exacerbation (IR: 23.8 [95% CI 22.6&#8211;25.0] per 100 PY) (<xref rid="f0003" ref-type="fig">Figure 3A&#8211;C</xref>). When stratified by sex and age, exacerbation rates trended toward being higher in females (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">Table S4</ext-link></underline>). Among the current and former smoker subgroups, 70.6% and 71.3%, respectively, had &#8805;1 exacerbation of any severity during follow-up; IRs for first exacerbation were similar in both groups (<xref rid="f0003" ref-type="fig">Figure 3A&#8211;C</xref>, <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">Table S4</ext-link></underline>, and <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">Figure S1A</ext-link></underline>). Exacerbations in the dual/triple therapy cohort are reported in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">Table S4</ext-link></underline>, <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">Figures S1B</ext-link>,</underline> and <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">S2</ext-link></underline>.
<fig position="float" id="f0003" fig-type="figure" orientation="portrait"><label>Figure 3</label><caption><p>Incidence Rates of a First COPD Exacerbation, for (<bold>A</bold>) Exacerbations of Any Severity, (<bold>B</bold>) Moderate Exacerbations, and (<bold>C</bold>) Severe Exacerbations, and (<bold>D</bold>) Death During Follow-up in the Triple Therapy Cohort.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="COPD-20-1851-g0003.jpg"/><attrib><bold>Notes</bold>: IRs were calculated as the ratio between the number of first events during follow-up and the number of 100 person-years of follow-up. A total of 1,623 patients in the triple therapy cohort had a recorded history of smoking; the stratified analyses were conducted in this subset of the triple therapy cohort.</attrib><attrib><bold>Abbreviations</bold>: COPD, chronic obstructive pulmonary disease; IR, incidence rate.</attrib></fig></p><p>During the follow-up period, 13.9% of patients in the triple therapy cohort died (IR: 8.0 [95% CI 7.4&#8211;8.6] per 100 PY). Mortality rates were higher in former smokers (IR: 11.3 [95% CI 9.6&#8211;13.2] per 100 PY) than current smokers (IR: 6.9 [95% CI 5.6&#8211;8.6] per 100 PY) (<xref rid="f0003" ref-type="fig">Figure 3D</xref> and <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">Figure S3A</ext-link></underline>) and increased with age and male sex (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">Table S5</ext-link></underline>). Results for the dual/triple therapy cohort are shown in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">Table S5</ext-link></underline>, <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">Figures S2</ext-link>,</underline> and <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">S3B</ext-link></underline>.</p></sec><sec id="s0003-s2004"><title>HCRU and HCRU-Related Costs</title><p>At the end of the 12-month follow-up, 3,290 patients (66.9%) in the triple therapy cohort remained alive and had continuous enrollment. Almost all patients had &#8805;1 ambulatory visit at baseline (98.9%) and during the 12-month follow-up (97.5%), and most had &#8805;1 ER visit (baseline, 76.7%; follow-up, 65.8%); mean (SD) total all-cause costs were $72,299 ($77,241) PPY and $63,178 ($77,061) PPY, respectively (<xref rid="t0003" ref-type="table">Table 3</xref>). COPD-related costs represented 47.9% of all-cause costs at baseline and 41.4% of all-cause costs during the 12-month follow-up (mean [SD] total cost: $34,645 [$47,334] PPY vs $26,153 [$47,085] PPY) (<xref rid="t0003" ref-type="table">Table 3</xref>). COPD-related ER visits occurred in 47.2% of patients at baseline and 33.4% of patients during follow-up, and COPD-related hospitalizations occurred in 43.3% and 23.5%, respectively. Similar trends in HCRU and HCRU-related costs were observed in the dual/triple therapy cohort (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/513573/513573-Revised-Supplementary-Information.docx" ext-link-type="uri">Table S6</ext-link></underline>).
<table-wrap position="float" id="t0003" orientation="portrait"><label>Table 3</label><caption><p>Healthcare Resource Utilization in Patients in the Triple Therapy Cohort During Baseline and the First 12 Months of Follow-up</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" colspan="1"/><th colspan="4" rowspan="1">Triple Therapy (N=3,290)</th></tr><tr><th colspan="2" rowspan="1">All-Cause HCRU</th><th colspan="2" rowspan="1">COPD-Related HCRU</th></tr><tr><th rowspan="1" colspan="1">Baseline (12 Months)</th><th rowspan="1" colspan="1">Follow-up (12 Months)</th><th rowspan="1" colspan="1">Baseline (12 Months)</th><th rowspan="1" colspan="1">Follow-up (12 Months)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>HCRU</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8805;1 Ambulatory visit, n (%)</td><td rowspan="1" colspan="1">3,254 (98.9)</td><td rowspan="1" colspan="1">3,206 (97.5)</td><td rowspan="1" colspan="1">3,049 (92.7)</td><td rowspan="1" colspan="1">2,705 (82.2)</td></tr><tr><td rowspan="1" colspan="1">Mean (SD) number of visits</td><td rowspan="1" colspan="1">30.7 (26.4)</td><td rowspan="1" colspan="1">28.7 (27.3)</td><td rowspan="1" colspan="1">6.0 (6.9)</td><td rowspan="1" colspan="1">4.6 (5.4)</td></tr><tr><td rowspan="1" colspan="1">&#8805;1 ER visit, n (%)</td><td rowspan="1" colspan="1">2,524 (76.7)</td><td rowspan="1" colspan="1">2,166 (65.8)</td><td rowspan="1" colspan="1">1,552 (47.2)</td><td rowspan="1" colspan="1">1,099 (33.4)</td></tr><tr><td rowspan="1" colspan="1">Mean (SD) number of visits</td><td rowspan="1" colspan="1">3.2 (5.1)</td><td rowspan="1" colspan="1">2.9 (6.7)</td><td rowspan="1" colspan="1">1.0 (1.6)</td><td rowspan="1" colspan="1">0.7 (1.7)</td></tr><tr><td rowspan="1" colspan="1">&#8805;1&#160;Hospitalization, n (%)</td><td rowspan="1" colspan="1">1,646 (50.0)</td><td rowspan="1" colspan="1">1,112 (33.8)</td><td rowspan="1" colspan="1">1,423 (43.3)</td><td rowspan="1" colspan="1">773 (23.5)</td></tr><tr><td rowspan="1" colspan="1">Mean (SD) number of hospitalizations</td><td rowspan="1" colspan="1">0.9 (1.4)</td><td rowspan="1" colspan="1">0.7 (1.5)</td><td rowspan="1" colspan="1">0.6 (1.0)</td><td rowspan="1" colspan="1">0.4 (0.9)</td></tr><tr><td colspan="5" rowspan="1"><bold>Mean (SD) PPY costs, $</bold></td></tr><tr><td rowspan="1" colspan="1">Ambulatory visits</td><td rowspan="1" colspan="1">12,350 (21,713)</td><td rowspan="1" colspan="1">12,083 (20,991)</td><td rowspan="1" colspan="1">1,578 (4,979)</td><td rowspan="1" colspan="1">1,321 (4,515)</td></tr><tr><td rowspan="1" colspan="1">ER visits</td><td rowspan="1" colspan="1">4,588 (8,270)</td><td rowspan="1" colspan="1">4,117 (9,407)</td><td rowspan="1" colspan="1">975 (2,255)</td><td rowspan="1" colspan="1">780 (2,723)</td></tr><tr><td rowspan="1" colspan="1">Hospitalizations</td><td rowspan="1" colspan="1">25,409 (54,342)</td><td rowspan="1" colspan="1">19,884 (55,136)</td><td rowspan="1" colspan="1">19,068 (45,830)</td><td rowspan="1" colspan="1">12,793 (43,917)</td></tr><tr><td rowspan="1" colspan="1">Office visits</td><td rowspan="1" colspan="1">4,426 (8,478)</td><td rowspan="1" colspan="1">4,435 (10,202)</td><td rowspan="1" colspan="1">622 (1,515)</td><td rowspan="1" colspan="1">566 (2,803)</td></tr><tr><td rowspan="1" colspan="1">Outpatient visits</td><td rowspan="1" colspan="1">7,924 (18,910)</td><td rowspan="1" colspan="1">7,647 (16,989)</td><td rowspan="1" colspan="1">956 (4,728)</td><td rowspan="1" colspan="1">756 (3,362)</td></tr><tr><td rowspan="1" colspan="1">Other medical services</td><td rowspan="1" colspan="1">12,548 (21,052)</td><td rowspan="1" colspan="1">12,161 (20,122)</td><td rowspan="1" colspan="1">3,041 (6,335)</td><td rowspan="1" colspan="1">2,938 (7,646)</td></tr><tr><td rowspan="1" colspan="1">Pharmacy</td><td rowspan="1" colspan="1">17,404 (21,931)</td><td rowspan="1" colspan="1">14,934 (18,724)</td><td rowspan="1" colspan="1">9,983 (4,620)</td><td rowspan="1" colspan="1">8,321 (4,954)</td></tr><tr><td rowspan="1" colspan="1">Total cost</td><td rowspan="1" colspan="1">72,299 (77,241)</td><td rowspan="1" colspan="1">63,178 (77,061)</td><td rowspan="1" colspan="1">34,645 (47,334)</td><td rowspan="1" colspan="1">26,153 (47,085)</td></tr></tbody></table><table-wrap-foot><fn id="tfn0005"><p><bold>Notes</bold>: Standardized costs were adjusted to 2021 US dollars using the annual medical care component of the Consumer Price Index to reflect inflation.<xref rid="cit0031" ref-type="bibr">31</xref></p></fn><fn id="tfn0006"><p><bold>Abbreviations</bold>: COPD, chronic obstructive pulmonary disease; ER, emergency room; HCRU, healthcare resource utilization; PPY, per patient-year.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="s0004"><title>Discussion</title><p>In this real-world data analysis of people with COPD who experience frequent moderate or severe exacerbations while receiving inhaled triple therapy, we identified&#160;a substantial clinical and healthcare burden.&#160;Mortality was high in this population, with death reported in approximately 8% of the cohort in a 12-month period and of those who survived, most experienced a subsequent exacerbation during follow-up. Trends in outcomes were similar among former and current smokers within this cohort, highlighting the overall disease burden experienced by this COPD population regardless of smoking status.</p><p>More than 1 in 10 people in the triple therapy cohort in this study died during the follow-up period of less than 2 years. These observations align with a recent UK study reporting a mortality rate of 7.5 per 100 PY in a COPD cohort who experienced &#8805;2 exacerbations over a 12-month period.<xref rid="cit0032" ref-type="bibr">32</xref> People in this study were also at high-risk of a subsequent exacerbation, with more than 70% experiencing an exacerbation during follow-up; the exacerbation rate was lower in this study (108 events per 100 PY) than in a previous US study using Medicare data, in which people who experienced &#8805;2 moderate exacerbations over a 12-month period had an exacerbation rate of 135 per 100 PY.<xref rid="cit0033" ref-type="bibr">33</xref> However, the higher exacerbation rates reported were likely attributable to the older age (mean age: 69.8 years) and greater comorbidity burden (mean CCI: 3.6) in that study cohort, and we would therefore consider these findings to broadly corroborate our own.</p><p>Individuals with COPD&#160;who experience exacerbations while receiving inhaled triple therapy experience a high comorbidity burden, with metabolic and cardiovascular diseases, such as hypertension, ischemic heart disease, type 2 diabetes, and CKD, being common comorbidities. A similar comorbidity profile was reported for a real-world COPD population receiving fixed&#160;inhaled triple therapy, in which high prevalence of cardiovascular comorbidities was also observed.<xref rid="cit0034" ref-type="bibr">34</xref> Treatments for COPD exacerbations aim to improve symptoms and resolve current exacerbations. In this study, the use of add-on COPD medications was very high with approximately 90% of patients receiving OCS and antibiotics for exacerbation management; however, these medications may be associated with adverse effects. A previous study has shown that people with COPD who were exposed to OCS had significantly higher risk of multiple adverse outcomes, including hypertension, type 2 diabetes, and CKD, compared with those not exposed to OCS.<xref rid="cit0035" ref-type="bibr">35</xref> Risk of osteoporosis was also 80% greater with exposure to OCS (vs no exposure),<xref rid="cit0035" ref-type="bibr">35</xref> which is an important factor for consideration noting the high average age of people affected by COPD. In this study, antibiotics were also received for an average of 41 days per year; this could lead to increased risk of antimicrobial resistance, which is a public health concern.<xref rid="cit0036" ref-type="bibr">36</xref></p><p>Aside from exacerbation-management medications, the COPD population in this study also frequently received oral add-on medications, such as LTRAs and PDE4 inhibitors, similar to prior studies.<xref rid="cit0037" ref-type="bibr">37</xref> However, LTRAs are not currently indicated in COPD, and use of some PDE4 inhibitors are associated with gastrointestinal adverse effects.<xref rid="cit0002" ref-type="bibr">2</xref> These suggest the lack of suitable therapies for this COPD population, highlighting an unmet medical need.</p><p>In this study, HCRU and related costs were largely sustained from baseline to follow-up; the lower values observed during follow-up are likely due to either regression to the mean effects from high baseline HCRU and costs or the decreased exacerbation risk following treatment as previously reported.<xref rid="cit0038" ref-type="bibr">38</xref> Other US studies have reported similarly high healthcare costs; one reported an average expenditure of $16,085 PPY for adults with COPD and another reported mean annual total healthcare costs of $22,130 for people with COPD, with costs increasing with disease severity (ranging $22,217&#8211;$31,148 for GOLD stage 1&#8211;4).<xref rid="cit0008" ref-type="bibr">8</xref>,<xref rid="cit0039" ref-type="bibr">39</xref> While differences in methodology and time periods may account for absolute differences in healthcare costs, these results reflect the high healthcare and economic burden of COPD, especially in those with comorbidities and severe disease.</p><p>In this study, 47% of patients receiving inhaled triple therapy with a history of smoking were current smokers. Although current smokers were younger than former smokers, exacerbation rates were similar, and the prevalence of cardiovascular comorbidities was comparable. This finding differs from other studies reporting improved exacerbation and mortality outcomes in former vs current smokers.<xref rid="cit0016" ref-type="bibr">16</xref> However, these prior studies assessed broad COPD populations in contrast to the more specific population in this study (those experiencing frequent moderate/severe exacerbations while receiving inhaled triple therapy), which could explain the difference in results. Overall, findings from this study emphasize the high burden of disease in this COPD population and the need for improved treatment options for all patients at risk of exacerbations, regardless of smoking status.</p><p>The heterogeneity of COPD poses a challenge for accurate diagnosis and effective management. While phenotypic classification has been historically used for diagnosis and treatment, the advent of the &#8220;treatable traits&#8221; approach may enable the implementation of personalized interventions for COPD.<xref rid="cit0040" ref-type="bibr">40</xref>,<xref rid="cit0041" ref-type="bibr">41</xref> The patient characteristics identified in this study could add to our understanding of pulmonary, extrapulmonary, and behavioural risk factors in exacerbating COPD, which could help refine the treatment selection to improve clinical outcomes and health-related quality of life for these patients.<xref rid="cit0040" ref-type="bibr">40</xref></p><sec id="s0004-s2001"><title>Strengths and Limitations</title><p>This study is subject to several limitations. First, although the database included a large cohort of people with COPD, those included were primarily insured through Medicare Advantage and may not be generalizable to all patients with COPD in real-world clinical practice. Second, Market Clarity does not capture some clinically relevant data such as disease severity, indicators of medication adherence, socioeconomic status, and other healthcare data, such as access to pulmonary rehabilitation, vaccinations, immunizations, and patient-reported outcomes. Claims data, and use of <italic toggle="yes">ICD-9/10</italic> codes for COPD diagnosis, are also prone to incomplete or miscoded diagnoses, an inherent limitation of claims-based studies, and missing data were not imputed. Mortality rates may have been underestimated, as some patients who died during follow-up may have been recorded as being lost to follow-up; however, substantial morbidity and mortality were still observed among the cohort assessed, emphasizing the disease burden in this population. Smoking status information was available in only one-third of people in the study; however, the baseline characteristics of current and former smokers were very similar to the triple therapy cohort. IRs for mortality and exacerbations were crude unadjusted estimates; nevertheless, results stratified by age and sex suggested an association between age or sex and mortality and exacerbation rates. This study may be considered outdated as it captured data prior to 2019; however, this was done intentionally to assess patient outcomes prior to the COVID-19 pandemic.</p></sec></sec><sec id="s0005"><title>Conclusions</title><p>This study highlights the considerable clinical and healthcare resource burden of COPD in those who experience frequent moderate or severe exacerbations while receiving inhaled triple therapy, with frequent exposure to add-on COPD therapies that have poor risk/benefit ratios. While air pollution, tobacco use, and lack of timely access to healthcare are known risk factors for COPD exacerbations, identification of other potential risk factors for frequent/severe exacerbations can aid in earlier diagnosis and prompt treatment. While smoking cessation is a key intervention in the management of COPD, the equally high disease burden observed in both current and former smokers highlights an unmet need to improve clinical management for all people with COPD regardless of smoking status.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was sponsored by AstraZeneca. Medical writing assistance was provided by Vanessa Ducas, PhD, and Magdalene Michael, PhD, of Envision Pharma Group and was funded by AstraZeneca.</p></ack><sec id="s0006"><title>Abbreviations</title><p>CCI, Charlson Comorbidity Index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ER, emergency room; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HCRU, healthcare resource utilization; <italic toggle="yes">ICD-9/10, International Classification of Diseases, 9th</italic> or <italic toggle="yes">10th Revision</italic>; ICS, inhaled corticosteroid; IR, incidence rate; LABA, long-acting &#946;2-agonist; LAMA, long-acting muscarinic antagonist; LTRAs, leukotriene receptor antagonists; OCS, oral corticosteroids; PDE4, phosphodiesterase 4; PPY, per patient-years; PY, person-years.</p></sec><sec sec-type="data-availability" id="s0007"><title>Data Sharing Statement</title><p>The data contained in our database contains proprietary elements owned by Optum and, therefore, cannot be broadly disclosed or made publicly available at this time. The disclosure of this data to third party clients assumes certain data security and privacy protocols are in place and that the third party client has executed our standard license agreement, which includes restrictive covenants governing the use of the data.</p></sec><sec id="s0008"><title>Ethical Statement</title><p>Institutional review board approval or waiver of approval was not required for this study, because the study data were secondary and deidentified in accordance with the United States Department of Health and Human Services Privacy Rule&#8217;s requirements for deidentification codified at 45 C.F.R. &#167; 164.514(b).</p></sec><sec id="s0009"><title>Author Contributions</title><p>All authors made a significant contribution to the work reported, whether in the conception, study design, execution, acquisition of data, and analysis and interpretation or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be submitted; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.</p></sec><sec sec-type="COI-statement" id="s0010"><title>Disclosure</title><p>CN, DC, MF, HM, JAA, and HDG are employees of AstraZeneca and may hold stocks/shares. PSV and TLB are employees of Optum Life Sciences. MCM reports NIH funding; royalties or licenses from UpToDate for authorship and editorial work for pulmonary function testing; consulting fees from Aridis, Boehringer Ingelheim, GlaxoSmithKline, MGC Diagnostics, and ndd Medical Technologies; and payment or honoraria from Talem Health for medical education for asthma and COPD. The authors report no other conflicts of interest in this work.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Celli</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Fabbri</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Criner</surname><given-names>G</given-names></string-name>, et al. <article-title>Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision</article-title>. <source><italic toggle="yes">Am J Respir Crit Care Med</italic></source>. <year>2022</year>;<volume>206</volume>(<issue>11</issue>):<fpage>1317</fpage>&#8211;<lpage>1325</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.202204-0671PP</pub-id><pub-id pub-id-type="pmid">35914087</pub-id><pub-id pub-id-type="pmcid">PMC9746870</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="webpage"><collab>Global Initiative for Chronic Obstructive Lung Disease (GOLD)</collab>. <article-title>Global Strategy for Prevention, Diagnosis, and Management of COPD: 2024 Report</article-title>; <year>2024</year>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://goldcopd.org/2024-gold-report/" ext-link-type="uri">https://goldcopd.org/2024-gold-report/</ext-link>. <date-in-citation>Accessed <month>November</month><day>20</day>, 2024</date-in-citation>.</mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="book"><collab>Forum of International Respiratory Societies</collab>. <article-title>The global impact of respiratory disease. Third edition</article-title>; <year>2021</year>. <publisher-name>European Respiratory Society</publisher-name>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://firsnet.org/images/publications/FIRS_Master_09202021.pdf" ext-link-type="uri">https://firsnet.org/images/publications/FIRS_Master_09202021.pdf</ext-link>. <date-in-citation>Accessed <month>November</month><day>20</day>, 2024</date-in-citation>.</mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Safiri</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Carson-Chahhoud</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Noori</surname><given-names>M</given-names></string-name>, et al. <article-title>Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019</article-title>. <source><italic toggle="yes">BMJ</italic></source>. <year>2022</year>;<volume>378</volume>:<fpage>e069679</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj-2021-069679</pub-id><pub-id pub-id-type="pmid">35896191</pub-id><pub-id pub-id-type="pmcid">PMC9326843</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>C-W</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>Y-Y</given-names></string-name>, et al. <article-title>Global, regional, and national burden of chronic respiratory diseases and associated risk factors, 1990-2019: results from the Global Burden of Disease Study 2019</article-title>. <source><italic toggle="yes">Front Med (Lausanne)</italic></source>. <year>2023</year>;<volume>10</volume>:<fpage>1066804</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmed.2023.1066804</pub-id><pub-id pub-id-type="pmid">37056726</pub-id><pub-id pub-id-type="pmcid">PMC10088372</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="webpage"><collab>Centers for Disease Control and Prevention, National Center for Health Statistics</collab>. <article-title>National Vital Statistics System, Mortality 2018-2022 on CDC WONDER online database, released in 2024. Data are from the Multiple Cause of Death Files, 2018-2022, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program</article-title>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://wonder.cdc.gov/ucd-icd10-expanded.html" ext-link-type="uri">http://wonder.cdc.gov/ucd-icd10-expanded.html</ext-link>. <date-in-citation>Accessed <month>November</month><day>20</day>, 2024</date-in-citation>.</mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Syamlal</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kurth</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Dodd</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Blackley</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>NB</given-names></string-name>, <string-name name-style="western"><surname>Mazurek</surname><given-names>JM</given-names></string-name>. <article-title>Chronic obstructive pulmonary disease mortality by industry and occupation &#8212; United States, 2020</article-title>. <source><italic toggle="yes">MMWR Morb Mortal Wkly Rep</italic></source>. <year>2020</year>;<volume>71</volume>:<fpage>1550</fpage>&#8211;<lpage>1554</lpage>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.mm7149a3</pub-id><pub-id pub-id-type="pmcid">PMC9762896</pub-id><pub-id pub-id-type="pmid">36480469</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mannino</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Mapel</surname><given-names>DW</given-names></string-name>, et al. <article-title>National and local direct medical cost burden of COPD in the United States from 2016 to 2019 and projections through 2029</article-title>. <source><italic toggle="yes">Chest</italic></source>. <year>2024</year>;<volume>165</volume>(<issue>5</issue>):<fpage>1093</fpage>&#8211;<lpage>1106</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chest.2023.11.040</pub-id><pub-id pub-id-type="pmid">38042365</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zafari</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Eakin</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Bellanger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Reed</surname><given-names>RM</given-names></string-name>. <article-title>Projecting long-term health and economic burden of COPD in the United States</article-title>. <source><italic toggle="yes">Chest</italic></source>. <year>2021</year>;<volume>159</volume>(<issue>4</issue>):<fpage>1400</fpage>&#8211;<lpage>1410</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chest.2020.09.255</pub-id><pub-id pub-id-type="pmid">33011203</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hurst</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Skolnik</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>GJ</given-names></string-name>, et al. <article-title>Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life</article-title>. <source><italic toggle="yes">Eur J Intern Med</italic></source>. <year>2020</year>;<volume>73</volume>:<fpage>1</fpage>&#8211;<lpage>6</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejim.2019.12.014</pub-id><pub-id pub-id-type="pmid">31954592</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lange</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lahmar</surname><given-names>ZM</given-names></string-name>, <string-name name-style="western"><surname>Martinez</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Bourdin</surname><given-names>A</given-names></string-name>. <article-title>Natural history and mechanisms of COPD</article-title>. <source><italic toggle="yes">Respirology</italic></source>. <year>2021</year>;<volume>26</volume>(<issue>4</issue>):<fpage>298</fpage>&#8211;<lpage>321</lpage>. doi:<pub-id pub-id-type="doi">10.1111/resp.14007</pub-id><pub-id pub-id-type="pmid">33506971</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hurst</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Vestbo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Anzueto</surname><given-names>A</given-names></string-name>, et al. <article-title>Susceptibility to exacerbation in chronic obstructive pulmonary disease</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2010</year>;<volume>363</volume>(<issue>12</issue>):<fpage>1128</fpage>&#8211;<lpage>1138</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa0909883</pub-id><pub-id pub-id-type="pmid">20843247</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Vanfleteren</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Boonen</surname><given-names>LMC</given-names></string-name>, <string-name name-style="western"><surname>Spruit</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Janssen</surname><given-names>DJA</given-names></string-name>, <string-name name-style="western"><surname>Wouters</surname><given-names>EFM</given-names></string-name>, <string-name name-style="western"><surname>Franssen</surname><given-names>FME</given-names></string-name>. <article-title>The superexacerbator phenotype in patients with COPD: a descriptive analysis</article-title>. <source><italic toggle="yes">ERJ Open Res</italic></source>. <year>2019</year>;<volume>5</volume>(<issue>2</issue>):<fpage>00235</fpage>&#8211;<lpage>2018</lpage>. doi:<pub-id pub-id-type="doi">10.1183/23120541.00235-2018</pub-id><pub-id pub-id-type="pmid">31192249</pub-id><pub-id pub-id-type="pmcid">PMC6546940</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mandru</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Pauley</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Burkes</surname><given-names>RM</given-names></string-name>. <article-title>Considerations for and mechanisms of adjunct therapy in COPD</article-title>. <source><italic toggle="yes">J Clin Med</italic></source>. <year>2021</year>;<volume>10</volume>(<issue>6</issue>):<fpage>1225</fpage>. doi:<pub-id pub-id-type="doi">10.3390/jcm10061225</pub-id><pub-id pub-id-type="pmid">33809583</pub-id><pub-id pub-id-type="pmcid">PMC7999347</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Martin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Burgel</surname><given-names>P-R</given-names></string-name>, <string-name name-style="western"><surname>Roche</surname><given-names>N</given-names></string-name>. <article-title>Inhaled dual phosphodiesterase 3/4 inhibitors for the treatment of patients with COPD: a short review</article-title>. <source><italic toggle="yes">Int J Chron Obstruct Pulmon Dis</italic></source>. <year>2021</year>;<volume>16</volume>:<fpage>2363</fpage>&#8211;<lpage>2373</lpage>. doi:<pub-id pub-id-type="doi">10.2147/copd.S226688</pub-id><pub-id pub-id-type="pmid">34429594</pub-id><pub-id pub-id-type="pmcid">PMC8378910</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nielsen</surname><given-names>AO</given-names></string-name>, <string-name name-style="western"><surname>Lange</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hilberg</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Farver-Vestergaard</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ibsen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>L&#248;kke</surname><given-names>A</given-names></string-name>. <article-title>COPD and smoking status - it does matter: characteristics and prognosis of COPD according to smoking status</article-title>. <source><italic toggle="yes">Chronic Obstr Pulm Dis</italic></source>. <year>2024</year>;<volume>11</volume>(<issue>1</issue>):<fpage>56</fpage>&#8211;<lpage>67</lpage>. doi:<pub-id pub-id-type="doi">10.15326/jcopdf.2023.0433</pub-id><pub-id pub-id-type="pmid">37828634</pub-id><pub-id pub-id-type="pmcid">PMC10913926</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Josephs</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Culliford</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>M</given-names></string-name>. <article-title>Improved outcomes in ex-smokers with COPD: a UK primary care observational cohort study</article-title>. <source><italic toggle="yes">Eur Respir J</italic></source>. <year>2017</year>;<volume>49</volume>(<issue>5</issue>):<fpage>1602114</fpage>. doi:<pub-id pub-id-type="doi">10.1183/13993003.02114-2016</pub-id><pub-id pub-id-type="pmid">28536250</pub-id><pub-id pub-id-type="pmcid">PMC5460640</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Vestbo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Papi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Corradi</surname><given-names>M</given-names></string-name>, et al. <article-title>Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial</article-title>. <source><italic toggle="yes">Lancet</italic></source>. <year>2017</year>;<volume>389</volume>(<issue>10082</issue>):<fpage>1919</fpage>&#8211;<lpage>1929</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0140-6736(17)30188-5</pub-id><pub-id pub-id-type="pmid">28385353</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kim</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Aaron</surname><given-names>SD</given-names></string-name>. <article-title>What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement</article-title>. <source><italic toggle="yes">Eur Respir J</italic></source>. <year>2018</year>;<volume>52</volume>(<issue>5</issue>):<fpage>1801261</fpage>. doi:<pub-id pub-id-type="doi">10.1183/13993003.01261-2018</pub-id><pub-id pub-id-type="pmid">30237306</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Papi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vestbo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fabbri</surname><given-names>L</given-names></string-name>, et al. <article-title>Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial</article-title>. <source><italic toggle="yes">Lancet</italic></source>. <year>2018</year>;<volume>391</volume>(<issue>10125</issue>):<fpage>1076</fpage>&#8211;<lpage>1084</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0140-6736(18)30206-x</pub-id><pub-id pub-id-type="pmid">29429593</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Benson</surname><given-names>VS</given-names></string-name>, <string-name name-style="western"><surname>Pascoe</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Siddall</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Small</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>M&#252;llerov&#225;</surname><given-names>H</given-names></string-name>. <article-title>Exacerbation frequency and eosinophil counts among patients with COPD currently prescribed triple therapy</article-title>. <source><italic toggle="yes">Int J Chron Obstruct Pulmon Dis</italic></source>. <year>2019</year>;<volume>14</volume>:<fpage>2711</fpage>&#8211;<lpage>2723</lpage>. doi:<pub-id pub-id-type="doi">10.2147/copd.S217503</pub-id><pub-id pub-id-type="pmid">31819403</pub-id><pub-id pub-id-type="pmcid">PMC6890196</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cheng</surname><given-names>W-C</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>B-R</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname><given-names>W-C</given-names></string-name>, et al. <article-title>When to use initial triple therapy in COPD: adding a LAMA to ICS/LABA by clinically important deterioration assessment</article-title>. <source><italic toggle="yes">Int J Chron Obstruct Pulmon Dis</italic></source>. <year>2020</year>;<volume>15</volume>:<fpage>3375</fpage>&#8211;<lpage>3384</lpage>. doi:<pub-id pub-id-type="doi">10.2147/copd.S279482</pub-id><pub-id pub-id-type="pmid">33376318</pub-id><pub-id pub-id-type="pmcid">PMC7764554</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Waeijen-Smit</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Houben-Wilke</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>DiGiandomenico</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gehrmann</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Franssen</surname><given-names>FME</given-names></string-name>. <article-title>Unmet needs in the management of exacerbations of chronic obstructive pulmonary disease</article-title>. <source><italic toggle="yes">Intern Emerg Med</italic></source>. <year>2021</year>;<volume>16</volume>(<issue>3</issue>):<fpage>559</fpage>&#8211;<lpage>569</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11739-020-02612-9</pub-id><pub-id pub-id-type="pmid">33616876</pub-id><pub-id pub-id-type="pmcid">PMC7897880</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kersul</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Cosio</surname><given-names>BG</given-names></string-name>. <article-title>Biologics in COPD</article-title>. <source><italic toggle="yes">Open Respir Arch</italic></source>. <year>2024</year>;<volume>6</volume>(<issue>2</issue>):<fpage>100306</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.opresp.2024.100306</pub-id><pub-id pub-id-type="pmid">38486675</pub-id><pub-id pub-id-type="pmcid">PMC10937225</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Riera-Mart&#237;nez</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>C&#224;naves-G&#243;mez</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Iglesias</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Martin-Medina</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cos&#237;o</surname><given-names>BG</given-names></string-name>. <article-title>The role of IL-33/ST2 in COPD and its future as an antibody therapy</article-title>. <source><italic toggle="yes">Int J Mol Sci</italic></source>. <year>2023</year>;<volume>24</volume>(<issue>10</issue>):<fpage>8702</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms24108702</pub-id><pub-id pub-id-type="pmid">37240045</pub-id><pub-id pub-id-type="pmcid">PMC10217986</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Plichta</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kuna</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Panek</surname><given-names>M</given-names></string-name>. <article-title>Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives</article-title>. <source><italic toggle="yes">Front Immunol</italic></source>. <year>2023</year>;<volume>14</volume>:<fpage>1207641</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2023.1207641</pub-id><pub-id pub-id-type="pmid">37334374</pub-id><pub-id pub-id-type="pmcid">PMC10272527</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ramakrishnan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Russell</surname><given-names>REK</given-names></string-name>, <string-name name-style="western"><surname>Mahmood</surname><given-names>HR</given-names></string-name>, et al. <article-title>Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial</article-title>. <source><italic toggle="yes">Lancet Respir Med</italic></source>. <year>2025</year>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(24)00299-6</pub-id><pub-id pub-id-type="pmid">39615502</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Blonde</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Khunti</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Meizinger</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Skolnik</surname><given-names>NS</given-names></string-name>. <article-title>Interpretation and impact of real-world clinical data for the practicing clinician</article-title>. <source><italic toggle="yes">Adv Ther</italic></source>. <year>2018</year>;<volume>35</volume>(<issue>11</issue>):<fpage>1763</fpage>&#8211;<lpage>1774</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12325-018-0805-y</pub-id><pub-id pub-id-type="pmid">30357570</pub-id><pub-id pub-id-type="pmcid">PMC6223979</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="webpage"><collab>Optum, Inc</collab>. <article-title>Market Clarity: linked EHR and Claims Data</article-title>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://business.optum.com/en/data-analytics/life-sciences/real-world-data/market-clarity-data.html" ext-link-type="uri">https://business.optum.com/en/data-analytics/life-sciences/real-world-data/market-clarity-data.html</ext-link>. <date-in-citation>Accessed <month>November</month><day>20</day>, 2024</date-in-citation>.</mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Quan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Couris</surname><given-names>CM</given-names></string-name>, et al. <article-title>Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries</article-title>. <source><italic toggle="yes">Am J Epidemiol</italic></source>. <year>2011</year>;<volume>173</volume>(<issue>6</issue>):<fpage>676</fpage>&#8211;<lpage>682</lpage>. doi:<pub-id pub-id-type="doi">10.1093/aje/kwq433</pub-id><pub-id pub-id-type="pmid">21330339</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="webpage"><collab>US Department of Labor, Bureau of Labor Statistics</collab>. <article-title>US Consumer Price Index</article-title>. <source>Medical Care. Series ID: CUUR0000SAM</source>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://data.bls.gov/cgi-bin/surveymost?cu" ext-link-type="uri">http://data.bls.gov/cgi-bin/surveymost?cu</ext-link>. <date-in-citation>Accessed <month>September</month><day>6</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Whittaker</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Rothnie</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Quint</surname><given-names>JK</given-names></string-name>. <article-title>Cause-specific mortality in COPD subpopulations: a cohort study of 339 647 people in England</article-title>. <source><italic toggle="yes">Thorax</italic></source>. <year>2024</year>;<volume>79</volume>(<issue>3</issue>):<fpage>202</fpage>&#8211;<lpage>208</lpage>. doi:<pub-id pub-id-type="doi">10.1136/thorax-2022-219320</pub-id><pub-id pub-id-type="pmid">37328279</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sethi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Make</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname><given-names>SB</given-names></string-name>, et al. <article-title>Relationship of COPD exacerbation severity and frequency on risks for future events and economic burden in the Medicare fee-for-service population</article-title>. <source><italic toggle="yes">Int J Chron Obstruct Pulmon Dis</italic></source>. <year>2022</year>;<volume>17</volume>:<fpage>593</fpage>&#8211;<lpage>608</lpage>. doi:<pub-id pub-id-type="doi">10.2147/copd.S350248</pub-id><pub-id pub-id-type="pmid">35342290</pub-id><pub-id pub-id-type="pmcid">PMC8948172</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Portillo</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Pollack</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>I</given-names></string-name>, et al. <article-title>Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study</article-title>. <source><italic toggle="yes">Ther Adv Respir Dis</italic></source>. <year>2023</year>;<volume>17</volume>:<fpage>17534666231164534</fpage>. doi:<pub-id pub-id-type="doi">10.1177/17534666231164534</pub-id><pub-id pub-id-type="pmid">37013423</pub-id><pub-id pub-id-type="pmcid">PMC10074608</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tse</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Emmanuel</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ariti</surname><given-names>C</given-names></string-name>, et al. <article-title>A long-term study of adverse outcomes associated with oral corticosteroid use in COPD</article-title>. <source><italic toggle="yes">Int J Chron Obstruct Pulmon Dis</italic></source>. <year>2023</year>;<volume>18</volume>:<fpage>2565</fpage>&#8211;<lpage>2580</lpage>. doi:<pub-id pub-id-type="doi">10.2147/copd.S433326</pub-id><pub-id pub-id-type="pmid">38022830</pub-id><pub-id pub-id-type="pmcid">PMC10657769</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Murray</surname><given-names>CJL</given-names></string-name>, <string-name name-style="western"><surname>Ikuta</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Sharara</surname><given-names>F</given-names></string-name>, et al. <collab>Antimicrobial Resistance Collaborators</collab>. <article-title>Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis</article-title>. <source><italic toggle="yes">Lancet</italic></source>. <year>2022</year>;<volume>399</volume>(<issue>10325</issue>):<fpage>629</fpage>&#8211;<lpage>655</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id><pub-id pub-id-type="pmid">35065702</pub-id><pub-id pub-id-type="pmcid">PMC8841637</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bogart</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Germain</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lalibert&#233;</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lejeune</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Duh</surname><given-names>MS</given-names></string-name>. <article-title>Real-world treatment patterns and switching following moderate/severe chronic obstructive pulmonary disease exacerbation in patients with commercial or Medicare insurance in the United States</article-title>. <source><italic toggle="yes">Int J Chron Obstruct Pulmon Dis</italic></source>. <year>2023</year>;<volume>18</volume>:<fpage>1575</fpage>&#8211;<lpage>1586</lpage>. doi:<pub-id pub-id-type="doi">10.2147/copd.S398816</pub-id><pub-id pub-id-type="pmid">37521022</pub-id><pub-id pub-id-type="pmcid">PMC10377554</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Anzueto</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Barjaktarevic</surname><given-names>IZ</given-names></string-name>, <string-name name-style="western"><surname>Siler</surname><given-names>TM</given-names></string-name>, et al. <article-title>Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter Phase III trials (the ENHANCE trials)</article-title>. <source><italic toggle="yes">Am J Respir Crit Care Med</italic></source>. <year>2023</year>;<volume>208</volume>(<issue>4</issue>):<fpage>406</fpage>&#8211;<lpage>416</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.202306-0944OC</pub-id><pub-id pub-id-type="pmid">37364283</pub-id><pub-id pub-id-type="pmcid">PMC10449067</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wallace</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Kaila</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bayer</surname><given-names>V</given-names></string-name>, et al. <article-title>Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population</article-title>. <source><italic toggle="yes">J Manag Care Spec Pharm</italic></source>. <year>2019</year>;<volume>25</volume>(<issue>2</issue>):<fpage>205</fpage>&#8211;<lpage>217</lpage>. doi:<pub-id pub-id-type="doi">10.18553/jmcp.2019.25.2.205</pub-id><pub-id pub-id-type="pmid">30698096</pub-id><pub-id pub-id-type="pmcid">PMC10397829</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Agusti</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bel</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>M</given-names></string-name>, et al. <article-title>Treatable traits: toward precision medicine of chronic airway diseases</article-title>. <source><italic toggle="yes">Eur Respir J</italic></source>. <year>2016</year>;<volume>47</volume>(<issue>2</issue>):<fpage>410</fpage>&#8211;<lpage>419</lpage>. doi:<pub-id pub-id-type="doi">10.1183/13993003.01359-2015</pub-id><pub-id pub-id-type="pmid">26828055</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Stolz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mkorombindo</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Schumann</surname><given-names>DM</given-names></string-name>, et al. <article-title>Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission</article-title>. <source><italic toggle="yes">Lancet</italic></source>. <year>2022</year>;<volume>400</volume>(<issue>10356</issue>):<fpage>921</fpage>&#8211;<lpage>972</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(22)01273-9</pub-id><pub-id pub-id-type="pmid">36075255</pub-id><pub-id pub-id-type="pmcid">PMC11260396</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>